- Home
- ATYR vs BNTC Comparison
ATYR vs BNTC Comparison
Compare ATYR & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- BNTC
- Stock Information
- Founded
- ATYR 2005
- BNTC 1995
- Country
- ATYR United States
- BNTC United States
- Employees
- ATYR N/A
- BNTC N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- ATYR Health Care
- BNTC Health Care
- Exchange
- ATYR Nasdaq
- BNTC Nasdaq
- Market Cap
- ATYR 327.0M
- BNTC 339.8M
- IPO Year
- ATYR 2015
- BNTC N/A
- Fundamental
- Price
- ATYR $2.79
- BNTC $13.01
- Analyst Decision
- ATYR Strong Buy
- BNTC Strong Buy
- Analyst Count
- ATYR 6
- BNTC 7
- Target Price
- ATYR $18.60
- BNTC $24.43
- AVG Volume (30 Days)
- ATYR 1.6M
- BNTC 62.0K
- Earning Date
- ATYR 03-13-2025
- BNTC 05-12-2025
- Dividend Yield
- ATYR N/A
- BNTC N/A
- EPS Growth
- ATYR N/A
- BNTC N/A
- EPS
- ATYR N/A
- BNTC N/A
- Revenue
- ATYR $235,000.00
- BNTC N/A
- Revenue This Year
- ATYR $1,387.23
- BNTC N/A
- Revenue Next Year
- ATYR $873.22
- BNTC N/A
- P/E Ratio
- ATYR N/A
- BNTC N/A
- Revenue Growth
- ATYR N/A
- BNTC N/A
- 52 Week Low
- ATYR $1.42
- BNTC $4.75
- 52 Week High
- ATYR $4.66
- BNTC $16.90
- Technical
- Relative Strength Index (RSI)
- ATYR 33.98
- BNTC 47.49
- Support Level
- ATYR $3.20
- BNTC $11.54
- Resistance Level
- ATYR $3.94
- BNTC $15.08
- Average True Range (ATR)
- ATYR 0.22
- BNTC 1.31
- MACD
- ATYR -0.09
- BNTC -0.39
- Stochastic Oscillator
- ATYR 4.97
- BNTC 27.43
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.